Universidade Federal de Sao Paulo
São Paulo, 04023900, Brazil
NCT Number: NCT03086759
Osteoarthritis of the knee is a very prevalent disease. However, there are few therapeutic options for its patients. Platelet-rich plasma is a treatment option for chronic pain. If proven to be effective in its intra-articular use, Platelet-rich plasma may help in the treatment of these patients.
Goal:
Primary objective: To compare effectiveness in improving pain and function and the medium-term tolerance (12 weeks) of intra-articular injection of Platelet-rich plasma versus intraarticular injection of triamcinolone hexacetonide in patients with symptomatic primary knee osteoarthritis.
Secondary objective: To compare the medium-term effectiveness of intra-articular injection of Platelet-rich plasma versus intra-articular injection of triamcinolone hexacetonide to improve synovial hypertrophy and quality of life in these patients.
Methods: A prospective randomized controlled double-blind study with three groups (each with n = 33) of patients with symptomatic osteoarthritis of knees who will receive intra-articular infiltration in a single moment. Patients will be allocated to one of three groups: 1) Platelet-rich plasma group: patients who will receive plasma; 2) triamcinolone hexacetonide Group: patients who will receive 40mg of triamcinolone hexacetonide; And 3) Isotonic saline solution group: patients who will receive isotonic saline solution. The patients will be evaluated by "blind" evaluators in 4 assessment times up to 12 weeks of follow-up through clinical assessment instruments (rest and movement pain, joint edema, goniometry, clinical improvement scale, quality of life questionnaire as the SF36), functional (Womac questionnaire, M. Lequesne Functional Knee Index, 6 min walk test, Time up and go test), and ultrasound test (quantitative and semiquantitative measurement of synovial hypertrophy and semiquantitative Power Doppler).
Statistics: The following statistical tests will be used according to the need: Student's t test, Mann-whitney, Pearson's chi-square test and ANOVA for repeated measures. A statistical significance of 5% will be considered.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Phase 4
São Paulo, 04023900, Brazil
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
intra-articular infiltration with platelet rich plasm
intra-articular infiltration withTriamcinolone Hexacetonide
intra-articular infiltration with Isotonic Saline Solution
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Evaluated using a visual analogue scale
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Evaluated using a visual analogue scale
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Evaluated using goniometry
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Evaluated using an improvement scale
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Using the SF-36 questionnaire
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Using the WOMAC questionnaire
Time frame: Baseline, after 4, 8, 12 and 56 weeks
Using the M Lequesne questionnaire
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Using the six minute walk test
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Using the time to up and go test
Time frame: Baseline, after 4, 8, 12 and 48 weeks
Using an ultrasound exam
Federal University of São Paulo
Other
Intra-Articular Use of Platelet Rich Plasma Versus Corticosteroid: A Clinical Trials in Osteoarthritis of Knee.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07327190
Arthritis, Joint Diseases
Kütahya, Turkey (Türkiye)
View Trial DetailsNCT04492670
Arthritis, Joint Diseases
Hong Kong
View Trial DetailsNCT04653896
Arthritis, Joint Diseases
The Bronx, New York, United States
View Trial DetailsNCT07717957
Arthritis, Joint Diseases
Kuantan, Pahang, Malaysia
View Trial Details